Severe Mitral Regurgitation and Cardiogenic Shock: Is Edge-to-Edge a Valid Strategy?

At present, cardiogenic shock continues to present high mortality despite the new treatments and ventricular assistance devices available in some centers. 

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

In this group, the presence of severe mitral regurgitation (MR) is around 5% and, on many occasions, it cannot be treated with surgery because of hemodynamic conditions. 

Edge-to-edge repair has been looked at by several studies with promising results. 

This study looked at patients from the STS/ACC, a registry of patients with cardiogenic shock and severe MR undergoing edge-to-edge repair with MitraClip. 

It included 3,797 patients. 3,249 (85.6%) were successfully implanted.

The populations were similar, mean age was 73, 60% were men, 80% were hypertensive, 2% had endocarditis, 37% prior MI, 35% prior PCI, and 64% atrial fibrillation.

MR was degenerative in 53,4% and STS was 15%.

Read also: IVUS Use in Peripheral Vascular Disease: Should this Tool Be Used More Frequently in Peripheral Interventions?

At 30 days, procedural complications were quite low, with no differences, but mortality was higher in those presenting device failure (16.4% vs. 9.1% p<0.001), as well as lower hospital stay (14.3 vs. 12.2 days p<0.001).

At one-year followup, mortality was lower among the successfully implanted (34.6% vs 55.5%; P < 0.001), with a number needed to treat (NNT) of 4.8 patients. Likewise, the combination of mortality and hospitalization for cardiac failure was lower in this group (29.6% vs 45.2%; P <0.001; NNT 6.4).

Conclusion

Reducing mitral regurgitation was possible in most patients with cardiogenic shock and was associated with significantly lower mortality and hospitalization for cardiac failure. Further randomized studies on Edge- to-edge in patients with cardiogenic shock are needed to establish the potential of this treatment. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Transcatheter Edge-to-Edge Mitral Valve Repair in Patients With Severe Mitral Regurgitation and Cardiogenic Shock.

Reference: Trevor Simard, et al. J Am Coll Cardiol 2022;80:2072–2084.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....